There is a lock for every key

Chemoproteomics-enabled identification of the targets of a hydroxylated cholesterol metabolite, 20(S)-hydroxycholesterol, reveals it to be the first reported endogenous ligand of the sigma-2 receptor, a drug target for neurodegeneration and neuropathic pain.

Automated summary

Through chemoproteomics technology, the study identified 20(S)-hydroxycholesterol as the first endogenous ligand of the sigma-2 receptor, a drug target for neurodegeneration and neuropathic pain.